SCHEMBL5264707

SCHEMBL5264707

CN(C)CC(N)c1cccnc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 3/20 0.46
CHRNA4 P43681 3/20 0.46
CFTR P13569 1/20 0.44
SLC6A2 P23975 1/20 0.44
SLC6A4 P31645 1/20 0.44
SLC6A3 Q01959 1/20 0.44
GOPC Q9HD26 1/20 0.44
KDM4E B2RXH2 1/20 0.44
CHRNA7 P36544 1/20 0.43
HRH1 P35367 3/20 0.42
HTR2A P28223 1/20 0.42
KCNA5 P22460 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
TDP1 Q9NUW8 1/20 0.41
LMNA P02545 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CYP2A6 P11509 1/20 0.40
CYP19A1 P11511 1/20 0.40
CYP2D6 P10635 2/20 0.39
CHRM1 P11229 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30705397 0.83 CHRNA7 (0.49) CHRNB2CHRNA4CFTRSLC6A2SLC6A4
SCHEMBL11972418 0.79 SMN1; SMN2 (0.50) CFTRSLC6A2SLC6A4SLC6A3GOPC
SCHEMBL11972446 0.79 SMN1; SMN2 (0.50) CFTRSLC6A2SLC6A4SLC6A3GOPC
SCHEMBL1515430 0.79 SMN1; SMN2 (0.50) CFTRSLC6A2SLC6A4SLC6A3GOPC
SCHEMBL29669002 0.79 SLC6A4 (0.48) CFTRSLC6A2SLC6A4SLC6A3GOPC
SCHEMBL1037866 0.79 SLC6A4 (0.48) CFTRSLC6A2SLC6A4SLC6A3GOPC
SCHEMBL6855637 0.79 SLC6A4 (0.48) CFTRSLC6A2SLC6A4SLC6A3GOPC
SCHEMBL3465672 0.79 SLC6A4 (0.48) CFTRSLC6A2SLC6A4SLC6A3GOPC
SCHEMBL6319993 0.79 SMN1; SMN2 (0.50) CHRNB2CHRNA4CFTRSLC6A2SLC6A4
Hydrochloric Acid SCHEMBL1439296 0.78 SMN1; SMN2 (0.48) CFTRSLC6A2SLC6A4SLC6A3GOPC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117098765-A Heterocyclic derivatives as Janus kinase inhibitors 奇斯药制品公司 2023-11-21 CN disclosed
CN-116981459-A Heterocyclic derivatives as janus kinase inhibitors 奇斯药制品公司 2023-10-31 CN disclosed
EP-2670764-A1 C-28 AMINES OF C-3 MODIFIED BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS Bristol-Myers Squibb Company (US) 2013-12-11 EP disclosed
EP-2576586-A1 C-28 AMIDES OF MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS Bristol-Myers Squibb Company (US) 2013-04-10 EP disclosed
WO-2012106188-A1 C-28 AMINES OF C-3 MODIFIED BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2012-08-09 WO disclosed
WO-2011153319-A1 C-28 AMIDES OF MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-12-08 WO disclosed
EP-1794135-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE Amgen Inc. (US) 2007-06-13 EP disclosed
WO-2006037117-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2006-04-06 WO disclosed
EP-1268431-A1 3-CYANOQUINOLINES,3-CYANO-1,6-NAPHTHYRIDINES, AND 3-CYANO-1,7-NAPHTHYRIDINES AS PROTEIN KINASE INHIBITORS Wyeth (US) 2003-01-02 EP disclosed
WO-2001072711-A1 3-CYANOQUINOLINES,3-CYANO-1,6-NAPHTHYRIDINES, AND 3-CYANO-1,7-NAPHTHYRIDINES AS PROTEIN KINASE INHIBITORS WYETH (US) 2001-10-04 WO disclosed